A Dose Block-randomized, Double-blind, Placebo- and Active-controlled, Single and Multiple Dosing, Dose-escalation Clinical Phase 1 Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2017
At a glance
- Drugs DWP 14012 (Primary) ; Esomeprazole
- Indications Peptic ulcer
- Focus Adverse reactions
- Sponsors Daewoong Pharmaceutical
- 23 Apr 2017 Status changed from recruiting to completed.
- 01 Nov 2016 Planned number of patients changed from 108 to 120.
- 01 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Feb 2017.